Mariannette Miller-Meeks (R-IA)

DRUG Act

H.R. 2214 · House bill Health

A Republican bill with 4 Democratic cosponsors · See all 6 cosponsors

Last activity — Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

In committee

Introduced and handed to a committee in the chamber it started in.

The committee holds it, and most bills are never heard from again. A hearing or a committee vote would be news; silence is the usual outcome, and it kills the bill without anyone voting against it.

Its path through Congress

  1. Introduced
  2. In Committee

What this bill would do

This bill, titled the "Delinking Revenue from Unfair Gouging Act" or the "DRUG Act," aims to improve services provided by pharmacy benefit managers. Starting January 1, 2027, it prohibits these managers from receiving remuneration for services or drug benefit administration, except for specific "bona fide service fees." These allowed fees must be flat dollar amounts and cannot be based on drug prices, discounts, or rebates. The law establishes strict enforcement through disgorgement of payments and daily civil penalties. It amends the Public Health Service Act, ERISA, and the Internal Revenue Code to implement these changes.

Yes· 3 of 6

  • Scored +6

    Does this lower the price of prescription medicines?

    The bill aims to lower prescription drug costs by ensuring rebates and discounts are passed through to plans rather than kept as profit by PBMs.

  • Scored +5

    Does this give people more protection from unfair business practices?

    The bill enhances consumer protection by preventing pharmacy benefit managers from using profit-driven drug pricing models.

  • Scored +4

    Does this lower what people pay for private health insurance?

    By decoupling service fees from drug prices, the bill may lead to lower net costs for insurance issuers and plans.

The opposite

No question was scored the opposite.